Observation Of Lenalidomide Plus Dexamethasone In Treatment Of Relapse/Refractory Multiple Myeloma

Objective: To observe the efficiency and adverse events oflenalidomide plus dexamethasone in treatment of relapse/refractorymultiple myeloma(RRMM).Methods: Of13patients who had received at least one previousantimyeloma therapy,9are relapse and4are refractory; according to theirprevious exposure to thalidomide, they were devided into2groups, theexposure group(7patients) and non-exposure group(6patients), all patientsreceived10-15mg of lenalidomide on days1to21of a28-day cycle, andreceived20mg of dexamethasone on days1to4,15to18for every cycle.Results: response was seen in9of13patients,5patients in exposuregroup and4patients in non-exposure group, overall response rate69%,2complete response(CR,15%);4patients were stable disease,2patients inexposure group and2patients in non-exposure group. Among the9 response patients, time to reponse was28days in7patients, and was56days in2patients, median time to reponse was28days.Conclusion: Lenalidomide plus dexmethasone in treatment of RRMMis effective and well toleranted, even for those who were exposured tothalidomide, it is also suitable for those with renal damage.